Drug updated on 3/28/2024
| Dosage Form | Tablet (oral; 2.5 mg, 5 mg, 10 mg) |
| Drug Class | Soluble guanylate cyclase stimulators |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- To reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.
Summary
- Vericiguat (Verquvo) is a drug used to reduce the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure and ejection fraction less than 45%.
- According to multiple studies, vericiguat has shown potential in preventing all causes of death, cardiovascular death, and hospitalizations due to heart failure irrespective of the atrial fibrillation status of patients. It was also found beneficial for patients with NT-proBNP levels up to 8000 pg/ml.
- However, some studies suggest that vericiguat's safety may not be up to standard especially at higher dosages but it still holds great potential as a breakthrough treatment for heart failure by improving disease severity.
- A meta-analysis indicated no significant difference between vericiguat group and placebo group regarding adverse effects or rates of cardiovascular deaths or HF-related hospitalization suggesting more clinical trials are required for verification.
- In comparison with other drugs like sacubitril/valsartan or sodium-glucose co-transporter-2 inhibitors (SGLT2i), there were mixed results on whether Verquvo had significantly lower risks associated with CV deaths or HF hospitalizations; however dapagliflozin was superior over Verquvo when considering risk reduction related specifically towards HF Hospitalisation.
- The information above is derived from eight systematic reviews/meta-analyses documents which included randomized controlled trials comparing efficacy and safety profiles among different patient populations suffering from Heart Failure conditions.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Verquvo (vericiguat) Prescribing Information. | 2023 | Merck Sharp and Dohme Corp., Rahway, NJ |